Instruction for use: Raloffect

Dosage form: Concentrate for solution for intravenous and intra-arterial administration, Tablets, Retard tablets

Active substance: Pentoxyphyllinum

ATX

C04AD03 Pentoxifylline

Pharmacological group

Antiaggregants

Adenosinergic agents

Angioprotectors and microcirculation correctors

The nosological classification (ICD-10)

G93.4 Unspecified Encephalopathy: bilirubin encephalopathy; lacunarity status; Tremor when portal-systemic encephalopathy; The latent hepatic encephalopathy; Atherosclerotic encephalopathy; Hypertensive encephalopathy; hypoxic encephalopathy; dismetabolic encephalopathy; Encephalopathy; brain lesion; Porto-caval encephalopathy; Vascular encephalopathy; Traumatic encephalopathy; encephalopathy; encephalopathy; Encephalopathy secondary genesis; Encephalopathy discirculatory; Encephalopathy portocaval; epileptic encephalopathy; hemorrhagic shock and encephalopathy syndrome; Subacute spongiform encephalopathy

H34.2 Other retinal arterial occlusions: Retinal vasospasm; Retinal artery thrombosis

H83 Other internal ear disorders: Disturbance of inner ear function; Violation of the inner ear function of vascular genesis; Disturbances of blood supply to the inner ear; Functional disorder of the inner ear

I63 Cerebral infarction: ischemic Stroke; Ischemic brain disease; Ischemic stroke; Ischemic stroke and its consequences; Ischemic cerebral stroke; Ischemic cerebrovascular accident; Ischemic brain damage; Ischemic brain damage; ischemic conditions; Cerebral ischemia; Acute hypoxia brain; Acute cerebral ischemia; Acute ischemic cerebrovascular accident; Acute cerebral infarction; Acute ischemic stroke; Acute period of ischemic stroke; Focal cerebral ischemia; Ischemic stroke; recurrent stroke; The syndrome of Morgagni-Adams-Stokes; Chronic cerebral ischemia; cerebrovascular stroke; embolic stroke; Ischemic brain damage

I67.2 Cerebral atherosclerosis: Atherosclerosis of the arteries of the brain; Atherosclerosis of cerebral vessels; Atherosclerotic changes in cerebral vessels; Vascular diseases of the brain; Sclerotic ischemic attacks; Sclerosis of cerebral vessels

I73.0 Raynaud's Syndrome: Raynaud's syndrome Leriche; Raynaud's disease; Raynaud's phenomenon; RaynaudLeriche syndrome; Raynaud's disease; Raynaud's syndrome with trophic disorders; Peripheral angiopathy

I74 Embolism and arterial thrombosis: Thrombosis of effort (stress); Arterial thrombosis; Arteriothrombosis; Subacute and chronic arterial thrombosis; Subacute thrombosis of peripheral arteries; Postoperative thrombosis; Vascular thrombosis; Vascular embolism; Thrombosis of aortocoronary shunt; Arterial thrombosis; Thrombosis of arteries; Coronary artery thrombosis; Coronary thrombosis; Thrombosis of blood vessels; Thrombosis with ischemic stroke; Thrombosis with general surgical operations; Thrombosis in Oncology Operations; Vascular thrombosis; Thrombus formation in the postoperative period; Thrombotic complications; Thromboembolic diseases; Thromboembolic syndrome; Thromboembolic complication in the postoperative period; Thromboembolism of arteries; Partial vascular thrombosis; Embolism; Embolism of arteries

I79.2 Peripheral angiopathy in diseases classified elsewhere: diabetic angiopathy; Angiopathy in diabetes; arteriosclerosis diabetic; Pain in lesions of peripheral nerves; Diabetic angiopathy; Diabetic microangiopathy; Diabetic vascular disease; Intermittent angioneurotic disbaziya; Macroangiopathy in diabetes; microangiopathy; Microangiopathy in diabetes mellitus; Tingling sensations in the hands and feet; Coldness in the extremities; Peripheral angiopathy; Peripheral arterial disease; Sclerosis Menkeberga; Chronic obliterating diseases of arteries

I82 Embolism and thrombosis of other veins: Recurrent venous thrombosis; Postoperative thrombosis; Venous thrombosis; Acute venous thromboembolism; Recurrent vein thrombosis; Venous thrombosis; Thrombosis of veins of internal organs; Venous thrombosis; Deep vein thrombosis; Thrombosis of blood vessels; Vascular thrombosis; Thrombosis of veins; Deep vein thrombosis; Thromboembolic diseases; Thromboembolism of veins; Severe venous thrombosis; Embolism; Embolism of veins; Thromboembolic complications

H83 Other internal ear disorders: Disturbance of inner ear function; Violation of the inner ear function of vascular genesis; Disturbances of blood supply to the inner ear; Functional disorder of the inner ear

I99 Other and unspecified disorders of the circulatory system: angiopathy; Arterial angiopathy; Atherosclerotic angiopathy; Hemodynamic right heart defects; Hemodynamic defect of the right heart; coronary angiopathy; Infringement of blood circulation; Violation of circulation; Violation microcirculation in organs and tissues; Peripheral circulatory disorders; Disorders of the peripheral circulation in the extremities; circulatory failure; Hemodynamic instability occlusion of arteriovenous origin; Acute circulatory failure; Psevdostenokardicheskie state; Psevdostenokardicheskoe disorder; circulatory disorder; Cardiovascular diseases; Vascular insufficiency; Thrombosis arteriovenous shunt; Thrombosis with prosthetic heart valves; Deterioration of blood circulation in the pelvic organs; Functional failure of the cardiovascular system; Functional disorders of the cardiovascular system; Chronic arterial insufficiency; Chronic heart failure; Age-related vascular disease; The risk of thrombosis

L87 Transepidermal perforations

R68.8 Other specified general symptoms and signs: Toxemia

T33-T35 Frostbite

Composition and release form

1 tablet contains pentoxifylline 200 mg, in a package of 50 pcs .; 1 tablet retard - 600 mg, in the package of 20, 50 and 100 pcs .; 1 ampoule with 5 ml solution for injection - 100 mg, in a package of 10 pcs .; 1 ampoule with 15 ml of concentrate for the preparation of the infusion solution - 300 mg, in the package 10 pcs.

Pharmacology

Mode of action - Vasodilator, antiaggregational, improving microcirculation, normalizing the rheological properties of blood.

Indications of Raloffect

Violations of peripheral circulation in the extremities (intermittent claudication, gangrene, ulcer of the lower leg, diabetic angiopathy, postthrombotic syndrome), ischemic stroke, impaired blood circulation of the eye, impaired blood flow to the inner ear.

Contraindications

Hypersensitivity, acute stage of myocardial infarction, massive hemorrhage.

Side effects

Headaches, dizziness, flickering before the eyes, anxiety, sleep disorders, falling blood pressure, tachycardia, stenocardia, cardiac rhythm disturbances, nausea, a feeling of heaviness in the epigastrium, vomiting, diarrhea, hemorrhage of the skin, mucous membranes, gastrointestinal tract, thrombocytopenia, aplastic Anemia, allergic reactions.

Interaction

Enhances the effect of beta-adrenomimetics, antihypertensive drugs, anticoagulants, insulin and oral hypoglycemic agents (in high doses).

Dosage and Administration

Doses of the drug are set individually. Tablets of 200 mg: treatment starts with a dose of 100 mg 3 times a day, slowly increasing to 200 mg 3 times a day. The maximum daily dose is 1.2 g, the maximum single dose is 400 mg. Tablets retard 600 mg: appoint 600 mg twice a day. Take the pill after eating, without chewing. Injectable forms are used in acute clinical situations and / or as a supplement to oral therapy. Solution for intravenous administration (1 ampoule / 100 mg): intravenously injected 100 mg 1-2 times a day. A combination with oral forms up to a total daily dose of 1.2-1.5 g. Solution for intravenous administration (1 ampoule / 300 mg): Adults and adolescents with a body weight of more than 50 kg are given 100 mg or 300 mg once a day Day intravenously drip in 250-500 ml infusion solution for 2-3 hours, in severe cases - maximum 200 mg or 300 mg 2 times a day with the same method of administration.

Storage conditions of Raloffect

Keep out of the reach of children.